ArticleFrontiers in neurology
Mortality trends in the United States for adults with concurrent cerebrovascular disease and pulmonary embolism.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary embolism (PE) and cerebrovascular disease are major global causes of mortality and may share common risk factors. This study analyzed U.S. all-cause mortality trends where PE and cerebrovascular diseases were recorded on the death certificate from 1999 to 2023. Methods: Using national all-cause mortality data for adults aged over 25 years whose death certificates recorded both PE (ICD-10 I26) and cerebrovascular diseases (ICD-10 I60-I69), we calculated age-adjusted mortality rates (AAMRs), standardized to the 2000 U.S. population. Joinpoint regression was applied to identify significant trends and compute annual and average annual percent changes (APC and AAPC). Subgroup analyses were performed by sex, age, race, region, and urbanization level. Results: Between 1999 and 2023, 59,075 U.S. deaths involved both pulmonary embolism and cerebrovascular disease, with 4,274 recorded in 2023. Age-adjusted mortality increased from 1.00 to 1.55 per 100,000 (AAPC: 1.93%), accelerating sharply during 2018-2021. Higher AAMR was observed in males, adults over 85 years, Non-Hispanic Black individuals, residents of the South, and non-metropolitan areas. Substantial geographic heterogeneity existed, with states such as Minnesota, Washington, Massachusetts, and Florida showing significant long-term upward trends. Conclusion: The accelerating mortality and pronounced disparities across demographic and geographic groups highlight the need for more precise public health strategies. Mitigating this burden requires targeted interventions for high-risk populations, equity-focused policies, improved healthcare access, geriatric-sensitive care, and strengthened infrastructure in vulnerable regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.